Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Hagop M. Kantarjian, Kun Hee Kim et al.|The Lancet Haematology|2022Cited by 242
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J. Short, Hagop M. Kantarjian, Muharrem Müftüoğlu et al.|Journal of Hematology & Oncology|2023Cited by 52
A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with <i>FLT3</i>-Mutated Acute Myeloid Leukemia: Results from a Phase I/II StudyNicholas J. Short, Farhad Ravandi, Courtney D. DiNardo et al.|Blood|2021Cited by 36
Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNicholas J. Short, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2021Cited by 26